Evidence map›Paper›PMID 36867174›Full record

ArticleAnnals of surgical oncology2023

Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence-The PIPAC-OPC4 Study.

Martin Graversen, I Rouvelas, A P Ainsworth, A P Bjarnesen, S Detlefsen, S B Ellebaek, C W Fristrup, M G Liljefors, L Lundell, M Nilsson and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. PIPAC for Gastrointestinal Malignancies.Journal of clinical medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Martin GraversenOdense PIPAC Center, Odense University Hospital, Odense, Denmark. martin.graversen@rsyd.dk.
I RouvelasDepartment of Upper Abdominal Diseases, Karolinska University Hospital and Division of Surgery and Oncology, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
A P AinsworthOdense PIPAC Center, Odense University Hospital, Odense, Denmark.
A P BjarnesenOdense PIPAC Center, Odense University Hospital, Odense, Denmark.
S DetlefsenOdense PIPAC Center, Odense University Hospital, Odense, Denmark.
S B EllebaekOdense PIPAC Center, Odense University Hospital, Odense, Denmark.
C W FristrupOdense PIPAC Center, Odense University Hospital, Odense, Denmark.
M G LiljeforsDepartment of Oncology, Karolinska University Hospital and Division of Surgery and Oncology, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
L LundellDepartment of Upper Abdominal Diseases, Karolinska University Hospital and Division of Surgery and Oncology, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
M NilssonDepartment of Upper Abdominal Diseases, Karolinska University Hospital and Division of Surgery and Oncology, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
P PfeifferOdense PIPAC Center, Odense University Hospital, Odense, Denmark.
L S TarpgaardOdense PIPAC Center, Odense University Hospital, Odense, Denmark.
A TsekrekosDepartment of Upper Abdominal Diseases, Karolinska University Hospital and Division of Surgery and Oncology, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
M B MortensenOdense PIPAC Center, Odense University Hospital, Odense, Denmark.
Odense University Hospital · DKKarolinska Institutet · SEUniversity of Southern Denmark · DKKarolinska University Hospital · SERegion of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with gastric adenocarcinoma (GAC) are at high risk of peritoneal recurrence despite perioperative chemotherapy and radical resection. This study evaluated feasibility and safety of laparoscopic D2 gastrectomy in combination with pressurized intraperitoneal aerosol chemotherapy (PIPAC).

methodsThis was a prospective, controlled bi-institutional study in patients with GAC at high risk of recurrence treated with PIPAC with cisplatin and doxorubicin (PIPAC C/D) after laparoscopic D2 gastrectomy. High risk was defined as a poorly cohesive subtype with predominance of signet-ring cells, clinical stage ≥ T3 and/or ≥ N2, or positive peritoneal cytology. Peritoneal lavage fluid was collected before and after resection. Cisplatin (10.5 mg/m

resultsTwenty-one patients were treated with a D2 gastrectomy and PIPAC C/D. The median age was 61 years (range 24-76), there were eleven female patients, and 20 patients had preoperative chemotherapy. There was no mortality. Two patients had grade 3b complications that were potentially related to PIPAC C/D (one anastomotic leakage, and one late duodenal blow-out). One patient had severe neutropenia, and nine patients had moderate pain. The LOS was 6 days (4-26). One patient had positive peritoneal lavage cytology before resection, and none were positive after. Fifteen patients had postoperative chemotherapy.

conclusionsLaparoscopic D2 gastrectomy in combination with PIPAC C/D is feasible and safe.

Indexed as

LaparoscopyPeritoneal NeoplasmsStomach NeoplasmsAdultAerosolsAgedCisplatinDoxorubicinFeasibility StudiesFemaleHumansMiddle AgedProspective StudiesYoung AdultAerosolsCisplatinDoxorubicin

Identifiers

PMID36867174
OpenAlexW4323035292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.